- Home
- CNOBP vs LYEL Comparison
CNOBP vs LYEL Comparison
Compare CNOBP & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNOBP | LYEL |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | 493 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 369.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CNOBP | LYEL |
|---|---|---|
| Price | $24.14 | $33.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | N/A | ★ 57.7K |
| Earning Date | N/A | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | N/A | $7.65 |
| 52 Week High | N/A | $35.16 |
Technical Indicators
Market Signals| Indicator | CNOBP | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 57.81 | 82.35 |
| Support Level | $24.03 | $20.59 |
| Resistance Level | $24.24 | $25.20 |
| Average True Range (ATR) | 0.11 | 2.69 |
| MACD | 0.02 | 1.16 |
| Stochastic Oscillator | 96.74 | 94.50 |
Price Performance
Historical ComparisonAbout CNOBP ConnectOne Bancorp Inc.
ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental and consumer wages.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.